Wave Life Sciences Ltd. Stock

$10.52

0.43% today

Nasdaq, Feb 28, 04:48 pm CET

ISIN

SG9999014716

Symbol

WVE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Wave Life Sciences Ltd. Stock price

$10.56

+2.71 34.52% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

-0.04 0.38%

ISIN

SG9999014716

Symbol

WVE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$1.61b
Enterprise Value	$1.33b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	24.90
P/S ratio (TTM) P/S ratio	30.04
P/B ratio (TTM) P/B ratio	11.06
Revenue growth (TTM) Revenue growth	-37.29%
Revenue (TTM) Revenue	$53.61m
EBIT (operating result TTM) EBIT	$-152.05m
Free Cash Flow (TTM) Free Cash Flow	$-143.07m
Cash position	$310.95m
EPS (TTM) EPS	$-1.11
P/E forward	negative
P/S forward	29.79
EV/Sales forward	24.69
Short interest	10.62%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Wave Life Sciences Ltd. Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Wave Life Sciences Ltd. forecast:

10x Buy

91%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Wave Life Sciences Ltd. forecast:

Buy

91%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Wave Life Sciences Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	54 54	37% 37% 100%
- Direct Costs	8.69 8.69	9% 9% 16%
Gross Profit	45 45	41% 41% 84%
- Selling and Administrative Expenses	39 39	21% 21% 73%
- Research and Development Expense	149 149	17% 17% 278%
EBITDA	-143 -143	72% 72% -267%
- Depreciation and Amortization	8.69 8.69	9% 9% 16%
EBIT (Operating Income) EBIT	-152 -152	64% 64% -284%
Net Profit	-143 -143	67% 67% -266%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Wave Life Sciences Ltd. Stock News

Neutral

GlobeNewsWire

●

3 days ago

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company's fourth quarter and full year 2024 financial results and provide busine...

Neutral

GlobeNewsWire

●

22 days ago

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation)

Positive

Seeking Alpha

●

about 2 months ago

Wave Life Sciences Is A Buy On Pipeline Prospects

Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and positive trial results have significantly boosted WVE's stock, despite previous flat performance and management missteps. Financially strong with $525M in cash, the Company has a solid runway for 8–...

More Wave Life Sciences Ltd. News

Company Profile

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Head office	Singapore
CEO	Paul Bolno
Employees	268
Founded	2012
Website	www.wavelifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now